title: Para-aortic lymph node metastasis in malignant dysgerminoma of the ovary.
abstract: Dysgerminomas comprise approximately 2-5% of all ovarian malignancies and mostly affect young adolescent women. Primary comprehensive surgery and adjuvant chemotherapy consisting of bleomycin, etoposide, and cisplatin (BEP) are the current recommended treatment options, the latter reserved for advanced stages (FIGO II-IV). We report two patients aged 20 and 26 years who presented with an initial FIGO stage IA, but inadequately assessed. Both were subsequently diagnosed with recurrent malignant dysgerminoma and para-aortic lymph node metastasis. Neither had received comprehensive staging at initial surgery nor adjuvant radio or chemotherapy. Both needed extensive surgery and multiagent chemotherapy for survival and belong to the small percentage of FIGO IA dysgerminoma patients showing a relapse. Comprehensive initial surgery including systematic para-aortic lymphadenectomy and adjuvant chemotherapy at tertiary referral centers is needed to minimize the treatment burden.
authors.affiliation: Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany. benjamin.kasenda@uniklinik-freiburg.de
authors.forename: Benjamin
authors.initials: B
authors.lastname: Kasenda
authors.forename: Philipp
authors.initials: P
authors.lastname: Harter
authors.forename: Tobias
authors.initials: T
authors.lastname: Hirsch
authors.forename: Alexander
authors.initials: A
authors.lastname: Ast
authors.forename: Christine
authors.initials: C
authors.lastname: Buhrmann
authors.forename: Florian
authors.initials: F
authors.lastname: Glaser
authors.forename: Andreas
authors.initials: A
authors.lastname: Du Bois
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D004407:Dysgerminoma / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000601:surgery; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin